Eli Lilly (LLY) Acquires Centessa for $7.8 Billion
Published on Β· Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowEli Lilly and Company (LLY) announced the acquisition of Centessa for $7.8 billion, with analyst estimates suggesting a market potential for Centessa's drugs of up to $20 billion. The company's stock rose 4.6% over the past five days and is up 18.6% year-over-year, despite a year-to-date decline of 13.4%. Additionally, on April 1, the FDA approved LLY's GLP-1 weight loss pill, Foundayo. Eli Lilly's aggressive investment marks its commitment to tackling challenging medical issues, which may enhance its market position moving forward.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Eli Lilly and Company (LLY)
Eli Lilly is a major pharmaceutical company known for diabetes and obesity treatments and a broad drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier LLY news
- Eli Lilly (LLY) Stock Rating Reiterated After Obesity Drug Approval
- Eli Lilly (LLY) Obesity Pill Foundayo Receives FDA Approval
- Eli Lilly (LLY) wins US approval for Foundayo weight-loss drug
- Eli Lilly (LLY) Receives FDA Approval for Obesity Pill
- Eli Lilly (LLY) GLP-1 Pill Approved: Launching Foundayo for Weight Loss
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
